Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA) Targeting Submission of NDA for LIQ861 in 1Q 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that third quarter 2019 financial results will be reported on Wednesday, November 13, 2019 .
View HTML
Toggle Summary Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin , Vice President of Global Commercial Development at
View HTML
Toggle Summary Liquidia to Present at Cantor 2019 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the
View HTML
Toggle Summary Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin , M.B., Ch.B., to the Company’s Board of Directors (the
View HTML
Toggle Summary Liquidia to Present at H.C. Wainwright Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the H.C.
View HTML
Toggle Summary Liquidia to Present at Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the 2019
View HTML
Toggle Summary Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Aug.
View HTML
Toggle Summary Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019
RESEARCH TRIANGLE PARK, N.C. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology , today announced
View HTML
Toggle Summary Liquidia and GSK Restructure Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
View HTML